Please login to the form below

Not currently logged in
Email:
Password:

ITP

This page shows the latest ITP news and features for those working in and with pharma, biotech and healthcare.

Roche Diagnostics among beneficiaries as NHS fast-tracks more tech

Roche Diagnostics among beneficiaries as NHS fast-tracks more tech

The fast track system is being conducted through the Innovation and Technology Payment (ITP) 2019/20, a new dedicated national budget for innovative diagnostics and devices, a move aimed at promoting ... It is especially exciting that two of our tests

Latest news

  • FDA clears Dova drug for liver-related low blood platelets FDA clears Dova drug for liver-related low blood platelets

    as the rare diseases idiopathic thrombocytopenia (ITP) and acquired severe aplastic anaemia. ... The US biotech says it has Revolade’s territory firmly in its sights, with plans to file for approval in ITP in the second half of the year, and is also

  • Rigel and Ultragenyx claim approvals for rare drugs Rigel and Ultragenyx claim approvals for rare drugs

    Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. ... ITP is a disease caused by low platelet counts that lead to bruising, bleeding and fatigue.

  • Rigel shaken after fostamatinib misses phase III trial target Rigel shaken after fostamatinib misses phase III trial target

    Shares in Rigel Pharmaceuticals fell yesterday after it revealed its lead drug candidate fostamatinib had failed a phase III trial in chronic/persistent immune thrombocytopenia (ITP), a disease leading to reduced ... ITP is an autoimmune disease where

  • CHMP backs orphan drugs Uptravi and Coagadex CHMP backs orphan drugs Uptravi and Coagadex

    new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP). ... Revlimid has been backed for the treatment of adult patients with relapsed or

  • Novartis bags EU approvals for three ex-GSK drugs Novartis bags EU approvals for three ex-GSK drugs

    Revolade - sold as Promacta in the US - has previously been approved to treat the rare disorder chronic immune thrombocytopenia (ITP) in Europe and is also authorised for both ITP and SAA ... Epstein said recent approvals in SAA and paediatric ITP will

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics